{"id":"NCT00597753","sponsor":"Affymax","briefTitle":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","officialTitle":"AFX01-12: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin Alfa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-07","completion":"2010-01","firstPosted":"2008-01-18","resultsPosted":"2012-07-30","lastUpdate":"2013-02-12"},"enrollment":803,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Renal Failure","Chronic Kidney Disease","Anemia"],"interventions":[{"type":"DRUG","name":"peginesatide","otherNames":["Omontys","Hematide","AF37702 Injection"]},{"type":"DRUG","name":"Epoetin Alfa","otherNames":["Epogen"]}],"arms":[{"label":"Peginesatide","type":"EXPERIMENTAL"},{"label":"Epoetin alfa","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.","primaryOutcome":{"measure":"Mean Change in Hemoglobin Between Baseline and the Evaluation Period","timeFrame":"Baseline and Weeks 29-36","effectByArm":[{"arm":"Peginesatide","deltaMin":11.3,"sd":0.523},{"arm":"Epoetin Alfa","deltaMin":11.32,"sd":0.493}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":89,"countries":["United States"]},"refs":{"pmids":["23343061","23343062"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":304,"n":524},"commonTop":["Cough","Nausea","Dyspnoea","Diarrhoea","Arteriovenous fistula site complication"]}}